This is setting up to be one of the major buying opportunities in some time. Mead Johnson (MJN) since it’s February 11 2009 spin-off inaugural debut close of $26.43 had risen to a recent high 0f $76.53 on December 21 when the death of a new born baby was linked to Enfamil which accounts for the majority of MJN revenue. Although there has been nothing conclusively linking this death to the Enfamil batch a number of retailers including Walmart have removed it from their shelves. It’s important to note that the Company states this batch was tested for Cronobacter (the cause of the baby’s death) and no products have yet been recalled. I’ve attached a link from Mead Johnson’s web site, so you can evaluate this for yourself. Since this news headline, the Company’s market value has gone down about 11 points or 15 points or to put it another way the death of this one baby unsubstantiated and unfortunate as it is has cost shareholder 15% of the market value of the Company. Another way of looking at it is this baby’s death cost the Company $2.23 billion dollars. Surely the most expensive if not one of the most expensive babies in history.
There was one report of another baby being infected with this RARE disease, Cronobacter, but apparently recovered and may not have even been exposed to the batch of Enfamil in question. And now both babies are reported to have consumed other brands of baby food. Of course none of this can be construed yet as being positive for Mead Johnson’s brand but much likely the Tylenol incident a few years back (which was linked to Johnson and Johnson) it’s highly unlikely if the world’s largest baby food company is going to suffer any kind of permanent financial damage from this in my opinion. But read this sampling of Wall Street research and gather your own conclusions:
It’s also really important to note that MJN is not only the spin-off of a highly respected major pharmaceutical company, Bristol Myers, but also one of the favorite investments of BMY’s long time CEO and current Non Executive Chairman of the Board, James Cornelius, who as recently as 8-9-11 bought 10,000 shares at $66.71. Cornelius I might add has been a steady buyer from the moment MJN spun-off from BMY and has accumulated 70,00 shares in open market purchase since it’s debut. You can make a strong argument that MJN was the crown jewel of Bristol Myers. If the stock goes down much more, you can be rest assured he will be a size buyer.So to the point, we recommended buying the stock below 60 as I think it’s run up too much anyway although apparently people more in the know than me disagree. Director Singer just bought 3000 shares at $70.28 on 11-17,21-11.
Ok, the same analysts that were conjuring you to be buyers of this stock at lifetime highs are not telling you to be cautions. Classic! The Sax Angle is telling you, no imploring you the get ready to step up the to the plate. If you can buy this home run under $60 pull out the checkbook. You don’t often get an XMAS gift tliel this or Hannuka. In spite of all the hysteria, it’s important to understand we are not talking about a recall. We are talking about the removal of a batch. Walmart is still selling Enfamil. In fact I visited Smith’s (owned by Kroger) our local store monopoly and examined a batch. It’s still for sale. None the less I’m a conservative type and would be willing to put my neck and money on the chopping block at below 60. We did that very thing by selling January 60 puts. Another option we are considering is buying the stock on the next dip (if there is one) and buying some puts five dollars below for some downside protection
15:25 EDT | MJN |
|
||||||
09:32 EDT | MJN |
|
||||||
09:32 EDT | MJN |
|
||||||
09:07 EDT | MJN |
|
||||||
08:38 EDT | MJN |
|
||||||
08:00 EDT | MJN |
|
||||||
07:13 EDT | MJN |
|
||||||
07:07 EDT | MJN |
|
||||||
December 22, 2011
|
||||||||
14:29 EDT | MJN | theflyonthewall.com: Mead Johnson says second sick baby did not take its product, Bloomberg says :theflyonthewall.com | ||||||
13:13 EDT | MJN |
|
||||||
09:49 EDT | MJN | theflyonthewall.com: Mead Johnson weakness a buying opportunity, says Deutsche Bank :theflyonthewall.com | ||||||
09:37 EDT | MJN |
|
Baby formula probe widens beyond EnfamilinFri Dec 23, 2011 5:46pm ESTReuters – U.S. health regulators said on Friday they are looking at several types of baby formula that could be linked to the death of an infant, expanding an investigation beyond Mead Johnsons market-leading Enfamil.An official from the Centers for Disease Control and Prevention CDC said the baby, 10-day-old Avery Cornett of Lebanon, Missouri, had consumed a variety of baby formulas before his death but declined to give more details.